MBX Biosciences Files Q3 2024 10-Q

TL;DR

MBX Biosciences Q3 10-Q is in: Stock details and R&D expenses are key.

AI Summary

MBX Biosciences, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported on its financial position, including common stock and preferred stock details. Key financial activities and disclosures related to its stock options and research and development expenses are highlighted.

Why It Matters

This filing provides investors with an update on MBX Biosciences' financial health and operational activities for the third quarter of 2024, crucial for understanding the company's trajectory.

Risk Assessment

Risk Level: medium — As a biotechnology company, MBX Biosciences is subject to inherent risks in drug development and market acceptance, which are reflected in its financial reporting.

Key Numbers

• Q3 2024 — Reporting Period (The 10-Q covers the third quarter of 2024.)
• 2024-09-30 — As of Date (The financial information is reported as of this date.)
• 2024-11-07 — Filing Date (The document was officially filed on this date.)

Key Players & Entities

• MBX Biosciences, Inc. (company) — Filer
• 20240930 (date) — Period of Report
• 20241107 (date) — Filing Date
• 0000950170-24-122840 (document_id) — Accession Number
• PHARMACEUTICAL PREPARATIONS [2834] (industry) — Standard Industrial Classification
• DE (state) — State of Incorporation
• 12406 HORESHAM STREET, CARMEL, IN 46032 (address) — Business and Mail Address

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share MBX The Nasdaq Global Sel

Filing Documents

• mbx-20240930.htm (10-Q) — 2537KB
• mbx-ex31_1.htm (EX-31.1) — 16KB
• mbx-ex31_2.htm (EX-31.2) — 16KB
• mbx-ex32_1.htm (EX-32.1) — 14KB
• 0000950170-24-122840.txt ( ) — 8144KB
• mbx-20240930.xsd (EX-101.SCH) — 1059KB
• mbx-20240930_htm.xml (XML) — 1148KB

Financial Statements (Unaudited)

Financial Statements (Unaudited) 5 Condensed Balance Sheets 5 Condensed Statements of Operations and Comprehensive Loss 6 Condensed Statements of Stockholders' Equity (Deficit) and Convertible Preferred Stock 7 Condensed Statements of Cash Flows 9 Notes to Unaudited Condensed Financial Statements 10 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 20 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 30 Item 4.

Controls and Procedures

Controls and Procedures 30 PART II. OTHER INFORMATION 31 Item 1.

Legal Proceedings

Legal Proceedings 31 Item 1A.

Risk Factors

Risk Factors 31 Item 2. Unregistered Sales of Equity Securities, Use of Proceeds and Issuer Purchases of Equity Securities 87 Item 3. Defaults Upon Senior Securities 88 Item 4. Mine Safety Disclosures 88 Item 5. Other Information 89 Item 6. Exhibits 90

Signatures

Signatures 92 i SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q (this "Quarterly Report") contains forward looking statements, including the sections entitled "Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Risk Factors". These sections contains express or implied forward-looking statements that are based on our management's belief and assumptions and on information currently available to our management. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or our future operational or financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements in this Quarterly Report include, but are not limited to, statements about: the initiation, timing, progress and results of our current and future research and development programs, preclinical studies and clinical trials; our ability to successfully complete our clinical trials; our ability to finalize the design or formulation of any product candidate; the ability of our platform to optimize pharmacokinetic and/or pharmacologic properties; our ability to advance any product candidates that we may identify and successfully complete any clinical studies, including the manufacture of any such product candidates; our ability to quickly leverage programs within our initial target indications and to progress additional programs to further develop our pipeline; our ability to internalize certain of our discovery capabilities; the prevalence of certain diseases and conditions we intend to treat and the size of the market opportunity for our product candidates; estimates of the numb

—FINANCIAL INFORMATION

PART I—FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements. MBX BIOSCIENCES, INC. CONDENSED BALANCE SHEETS (in thousands, except share and per share amounts) September 30, December 31, 2024 2023 (Unaudited) Assets Current assets: Cash and cash equivalents $ 132,865 $ 30,523 Marketable securities 144,198 50,153 Prepaid expenses and other current assets 4,107 2,789 Total current assets 281,170 83,465 Property and equipment, net 1,033 439 Right-of-use assets 147 226 Other assets 50 50 Total assets $ 282,400 $ 84,180 Liabilities, Convertible Preferred Stock and Stockholders' Equity (Deficit) Current liabilities: Accounts payable $ 5,002 $ 1,391 Accrued expenses 5,752 2,382 Operating lease liability, current 166 153 Total current liabilities 10,920 3,926 Share repurchase liability 68 194 Operating lease liability, net of current 44 171 Total liabilities 11,032 4,291 Commitments and contingencies (Note 9) Convertible preferred stock Series A Convertible Preferred Stock, $ 0.0001 par value, zero shares authorized, issued and outstanding as of September 30, 2024 and 53,598,587 shares authorized, issued and outstanding (liquidation preference of $ 36,822,229 ) as of December 31, 2023 — 36,501 Series B Convertible Preferred Stock, $ 0.0001 par value, zero shares authorized, issued and outstanding as of September 30, 2024 and 129,240,032 shares authorized, issued and outstanding (liquidation preference of $ 116,316,029 ) as of December 31, 2023 — 115,856 Total convertible preferred stock — 152,357 Stockholders' equity (deficit) Undesignated preferred stock, $ 0.0001 par value, 10,000,000 shares authorized and zero issued and outstanding as of September 30, 2024 and zero shares authorized, issued and outstanding as of December 31, 2023 — — Common stock, $ 0.0001 par value, 500,000,000 shares authorized and 33,376,058 issued and outstanding as of Se

View Full Filing

View this 10-Q filing on SEC EDGAR